EAN 2026 | Adverse events of special interest during the RCP: Myasthenia Gravis Inebilizumab Trial

Richard Nowak, MD, MS, Yale School of Medicine, New Haven, CT, discusses adverse events of special interest during the randomized controlled period (RCP) of the Myasthenia Gravis Inebilizumab Trial (MINT; NCT04524273). Dr Nowak highlights that this analysis demonstrated the favorable safety profile for inebilizumab in participants with generalized myasthenia gravis. This interview took place at the 12th Congress of the European Academy of Neurology (EAN) in Geneva, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.